<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00268684</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-05-FB-05235-CTIL</org_study_id>
    <nct_id>NCT00268684</nct_id>
  </id_info>
  <brief_title>Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC</brief_title>
  <official_title>A Phase III Trial Comparing Whole Brain Radiation (WBRT) and Stereotactic Radiosurgery (SRS) Alone Versus With Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and 1-3 Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <brief_summary>
    <textblock>
      The objectives of the study is to determine if either temozolomide or erlotinib combined with&#xD;
      WBRT and SRS improves survival as compared to WBRT and SRS alone.Ptients with histologically&#xD;
      confirmed NSCLC with the presence of 1-3 intraparenchymal brain metastases will be randomized&#xD;
      to 3 arms. All of the patients will receive WBRT and SRS. The patients of the arm 1 will&#xD;
      receive radiation treatment only, the arm 2 patients will be treated with temozolomide and&#xD;
      arm 3 patients will receive erlotinib&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <primary_outcome>
    <measure>survival</measure>
  </primary_outcome>
  <enrollment>381</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Neoplasm Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib, Temozolomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed non-small cell lung cancer with the presence of 1-3&#xD;
             intraparenchymal brain metastases.&#xD;
&#xD;
          2. A contrast-enhanced MRI demonstrating the presence of 1-3 brain metastases performed&#xD;
             within two weeks prior to registration.&#xD;
&#xD;
          3. The contrast-enhancing intraparenchymal brain tumor must be well circumscribed and&#xD;
             must have a maximum diameter of â‰¤ 4.0 cm in any direction on the enhanced scan. If&#xD;
             multiple lesions are present and one lesion is at the maximum diameter, the other(s)&#xD;
             must not exceed 3.0 cm in maximum diameter.&#xD;
&#xD;
          4. Patients who present with symptoms of brain metastases at the time of initial&#xD;
             diagnosis are eligible and do not need to demonstrate one month of stable scans.&#xD;
&#xD;
          5. Age 18 years or older.&#xD;
&#xD;
          6. Zubrod 0-1&#xD;
&#xD;
          7. Neurologic Function Status 0, 1, or 2.&#xD;
&#xD;
          8. Patients may have stable extracranial metastases.&#xD;
&#xD;
          9. Contrast-enhancing CT scans of the chest, abdomen and pelvis, and bone scan to&#xD;
             determine the extent of extracranial malignant disease.&#xD;
&#xD;
         10. Adequate bone marrow reserve&#xD;
&#xD;
         11. Patients randomized to receive erlotinib who are on enzyme inducing seizure medicines&#xD;
             including phenytoin, carbamazepine, rifampicin, barbiturates must be converted to a&#xD;
             nonenzyme inducing anti-seizure medication. Patients on Arm 3 will not be able to&#xD;
             start treatment immediately if converting.&#xD;
&#xD;
         12. Patient must sign a study-specific informed consent form. If the patient's mental&#xD;
             status precludes his/her giving informed consent, written informed consent may be&#xD;
             given by the patient's legal representative.&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major medical illnesses or psychiatric impairment&#xD;
&#xD;
          2. Patients who have undergone a complete resection of all known brain&#xD;
             metastases.Patients who have undergone subtotal resection are eligible providing&#xD;
             residual disease is =/&lt; 4.0 cm in maximum diameter.&#xD;
&#xD;
          3. Inability to obtain histologic proof of NSCLC.&#xD;
&#xD;
          4. Patients with leptomeningeal metastases documented by MRI or CSF evaluation.&#xD;
&#xD;
          5. Clinical or radiographic evidence of progression (other than the study lesion(s))&#xD;
             within one month prior to enrollment. (Patients who have brain metastases at initial&#xD;
             presentation are eligible and do not need to demonstrate one month of stable scans).&#xD;
&#xD;
          6. Patients with metastases within 10 mm of the optic apparatus so that some portion of&#xD;
             the optic nerve or chiasm would be included in the high dose SRS boost field.&#xD;
&#xD;
          7. Patients with metastases in the brainstem, midbrain, pons, or medulla.&#xD;
&#xD;
          8. Patients with liver metastases.&#xD;
&#xD;
          9. Previous cranial radiation.&#xD;
&#xD;
         10. Women who are pregnant or nursing&#xD;
&#xD;
         11. Patients who are HIV positive are not eligible.&#xD;
&#xD;
         12. Any evidence of clinically active interstitial lung disease&#xD;
&#xD;
         13. Treatment with a non-approved or investigational drug within 30 days before Day 1 of&#xD;
             studytreatment.&#xD;
&#xD;
         14. Concomitant use of St. John's Wort.&#xD;
&#xD;
         15. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to erlotinib and temozolomide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix Bokstein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lina Veisenman</last_name>
    <phone>972-36977285</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felix Bokstein, M.D.</last_name>
    <phone>972-524266532</phone>
    <email>fbok@netvision.net.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>63409</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Bokstein, M.D.</last_name>
      <phone>972-524266532</phone>
      <email>fbok@netvision.net.il</email>
    </contact>
    <contact_backup>
      <last_name>Debora Blumenthal, M.D.</last_name>
      <phone>972-524266403</phone>
      <email>dvorab@tasmc.gov.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2005</verification_date>
  <study_first_submitted>December 21, 2005</study_first_submitted>
  <study_first_submitted_qc>December 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2005</study_first_posted>
  <last_update_submitted>February 27, 2006</last_update_submitted>
  <last_update_submitted_qc>February 27, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

